Presepsin: a biomarker of early-onset neonatal sepsis

Abstract

Neonatal early-onset sepsis represents one of the most common diseases leading to morbidity and mortality in preterm infants. A prompt diagnosis is still a challenge in the clinical practice due to several biases affecting the current standard of care performance. In this regard, the soluble cluster of differentiation CD14 subtype, namely Presepsin, has been shown to be a promising diagnostic biomarker of sepsis in newborns. Although Presepsin provides high accuracy and short results output, its reliability in daily clinical practice is still an issue that needs further investigation. Therefore, in the present review we offer an overview of Presepsin role as diagnostic tool of early-neonatal onset sepsis.